Trial Profile
SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Sirolimus (Primary)
- Indications Nerve sheath neoplasms; Neurofibromatosis 1
- Focus Therapeutic Use
- 22 Dec 2023 Status changed from active, no longer recruiting to completed.
- 15 Dec 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.
- 15 Dec 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.